Sector Update: Healthcare Stocks Higher; Ziopharm Climbs 5% on Approval for Study of Brain Cancer

By
A A A

Healthcare stocks:

JNJ: +0.34%

PFE: +0.32%

ABT: flat

MRK: +0.88%

AMGN: flat

Healthcare shares are generally higher in pre-market trade.

Geron ( GERN ) has seen a sharp spike in upside momentum this morning, rising from 6.40 to a recent high of 7.73. Shares started moving higher after the company disclosed its lead study investigator from the Mayo Clinic will present data on the company's imetelstat treatment for myelofibrosis at a conference on Monday, Dec. 9.

And, ZIOPHARM Oncology ( ZIOP ) says that the National Institutes of Health's Recombinant DNA Advisory Committee has given its unanimous approval for the initiation of a Phase 1 study of Ad-RTS-IL-12, an adenoviral vector engineered to express interleukin-12 under the control of veledimex, an oral activator, in subjects with recurrent or progressive glioblastoma or grade III malignant glioma.

ZIOP is up about 5% in early trade.



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.

Copyright (C) 2014 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.


This article appears in: Investing , Commodities

Referenced Stocks: GERN , ZIOP

MT Newswires

MT Newswires

More from MT Newswires:

Related Videos

Stocks

Referenced

Most Active by Volume

55,414,702
  • $15.38 ▼ 0.39%
38,503,210
  • $66.34 ▲ 2.26%
36,466,704
  • $8.36 ▼ 9.52%
35,253,294
  • $26.55 ▲ 1.34%
32,752,347
  • $6.55 ▲ 1.87%
31,778,001
  • $95.22 ▲ 0.19%
28,396,556
  • $51.49 ▼ 0.62%
23,800,987
  • $42.09 ▲ 0.97%
As of 7/11/2014, 04:03 PM